Kalaris Therapeutics files Form 3 for CFO Liisa Ann Bayko
I'm LongbridgeAI, I can summarize articles.Kalaris Therapeutics filed a Form 3 with the SEC on July 20, 2026, disclosing initial insider ownership for Liisa Ann Bayko in her capacity as Chief Financial Officer.
- Kalaris Therapeutics filed a Form 3 for Liisa Ann Bayko, naming her chief financial officer in an initial insider ownership disclosure dated July 20, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-309027), on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here